Mike I. Walton

1.2k total citations
9 papers, 856 citations indexed

About

Mike I. Walton is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Mike I. Walton has authored 9 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Mike I. Walton's work include Cancer-related Molecular Pathways (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Biochemical and Molecular Research (3 papers). Mike I. Walton is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Biochemical and Molecular Research (3 papers). Mike I. Walton collaborates with scholars based in United Kingdom and United States. Mike I. Walton's co-authors include Paul Workman, Michelle D. Garrett, Florence I. Raynaud, Timothy A. Yap, Johann S. de Bono, Steven R. Whittaker, Stuart C. Wilson, Amin Mirza, Ian R. Hardcastle and Suzanne A. Eccles and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Mike I. Walton

9 papers receiving 840 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mike I. Walton United Kingdom	7	630	283	118	112	93	9	856
Lora B. Kramer United States	22	871 1.4×	298 1.1×	87 0.7×	82 0.7×	103 1.1×	34	1.2k
Alice Hlobílková Czechia	15	576 0.9×	252 0.9×	170 1.4×	57 0.5×	87 0.9×	26	889
Lynn Ueno United States	9	630 1.0×	221 0.8×	148 1.3×	75 0.7×	76 0.8×	13	910
Steven L. Abrams United States	8	711 1.1×	340 1.2×	180 1.5×	149 1.3×	43 0.5×	9	1.0k
Xianping Shi China	20	683 1.1×	261 0.9×	148 1.3×	48 0.4×	72 0.8×	35	1.0k
Nancy De Nève Belgium	17	490 0.8×	211 0.7×	216 1.8×	90 0.8×	56 0.6×	31	961
Giacomo Cossa Italy	17	650 1.0×	352 1.2×	148 1.3×	81 0.7×	113 1.2×	26	926
Ignacio Dolado Spain	11	695 1.1×	333 1.2×	170 1.4×	107 1.0×	90 1.0×	20	1.0k
Α. Φωτίου United Kingdom	14	339 0.5×	208 0.7×	97 0.8×	141 1.3×	114 1.2×	23	755
Chris J. Novotny United States	9	642 1.0×	179 0.6×	82 0.7×	81 0.7×	38 0.4×	10	829

Countries citing papers authored by Mike I. Walton

Since Specialization

Citations

This map shows the geographic impact of Mike I. Walton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike I. Walton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike I. Walton more than expected).

Fields of papers citing papers by Mike I. Walton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike I. Walton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike I. Walton. The network helps show where Mike I. Walton may publish in the future.

Co-authorship network of co-authors of Mike I. Walton

This figure shows the co-authorship network connecting the top 25 collaborators of Mike I. Walton. A scholar is included among the top collaborators of Mike I. Walton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike I. Walton. Mike I. Walton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Walton, Mike I., Paul D. Eve, Angela Hayes, et al.. (2012). CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research. 18(20). 5650–5661. 69 indexed citations

Yap, Timothy A., Mike I. Walton, Melanie Valenti, et al.. (2010). Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics. 10(2). 360–371. 59 indexed citations

Yap, Timothy A., Simon P. Heaton, Mike I. Walton, et al.. (2010). AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth. Molecular Cancer Therapeutics. 9(5). 1100–1110. 50 indexed citations

Yap, Timothy A., Kyriakos P. Papadopoulos, Ivy Fearen, et al.. (2010). Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade. Cancer Research. 70(8_Supplement). 27–27. 3 indexed citations

Yap, Timothy A., Michelle D. Garrett, Mike I. Walton, et al.. (2008). Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Current Opinion in Pharmacology. 8(4). 393–412. 445 indexed citations

Walton, Mike I., Stuart C. Wilson, Ian R. Hardcastle, Amin Mirza, & Paul Workman. (2005). An evaluation of the ability of pifithrin-α and -β to inhibit p53 function in two wild-type p53 human tumor cell lines. Molecular Cancer Therapeutics. 4(9). 1369–1377. 56 indexed citations

Clarke, Paul A., Katharine Pestell, Francesca Di Stefano, Paul Workman, & Mike I. Walton. (2004). Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo. British Journal of Cancer. 91(8). 1614–1623. 17 indexed citations

Whittaker, Steven R., Mike I. Walton, Michelle D. Garrett, & Paul Workman. (2004). The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway. Cancer Research. 64(1). 262–272. 153 indexed citations

Walton, Mike I., William Gibson, G. Wynne Aherne, et al.. (1996). Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.. Journal of Pharmacology and Experimental Therapeutics. 277(2). 909–916. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact